Reckitt Benckiser plans to spin off its pharmaceuticals business during the next 12 months, according to Bloomberg reports.  The deal will be listed in the U.K., and the company may retain a stake after the spinoffs.  Most of the division’s revenues reportedly come from Suboxone, used to treat opinoid addiction. The company is reportedly focusing on consumer healthcare, Bloomberg reports.